<?xml version="1.0" encoding="UTF-8"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:content="http://purl.org/rss/1.0/modules/content/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://www.gourt.com/Health/Medicine/Medical-Specialties/Pathology.html">
<title>Pathology RSS : Gourt</title>
<link>http://www.gourt.com/Health/Medicine/Medical-Specialties/Pathology.html</link>
<description></description>
<dc:language>en-us</dc:language>
<dc:rights>Copyright 2007, Gourt.com</dc:rights>
<dc:date>2009-11-07T23:50+04:00
</dc:date>
<dc:publisher>rtruog@gourt.com</dc:publisher>
<dc:creator>rtruog@gourt.com</dc:creator>
<dc:subject>Pathology RSS : Gourt</dc:subject>
<syn:updatePeriod>hourly</syn:updatePeriod>
<syn:updateFrequency>1</syn:updateFrequency>
<syn:updateBase>1901-01-01T00:00+00:00</syn:updateBase>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_minnesota/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_arizona/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_mexico/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_york/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_florida/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_louisiana/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_georgia/page_1.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_3.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_dakota/page_2.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_virginia/page_3.html" />
  <rdf:li rdf:resource="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_texas/page_2.html" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/29" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/28" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/27" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/26" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/25" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/24" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/23" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/22" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/21" />
  <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/8/1/20" />
 </rdf:Seq>
</items>
</channel>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_minnesota/page_1.html">
<title>Seeking Skilled Pathologist for Medical Director Position in Midwest :: Minnesota :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_minnesota/page_1.html</link>
<description><![CDATA[Job 9110540 A large, well established Pathology Group in the Midwest is seeking an experienced Pathologist to serve as director.  If you are an excellent communicator and educator, with leadership background ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_arizona/page_2.html">
<title>Fellowship Trained Dermatopathologist needed in Sunny Metro Arizona :: Arizona :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_arizona/page_2.html</link>
<description><![CDATA[Job 919845 Fellowship Trained Dermatopathologist needed in Sunny Metro Arizona   Fellowship Trained Dermatopathologist urgently needed for a growing business Serve two area hospitals Board certification ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_2.html">
<title>Facility in Pennsylvania has excellent opportunity for Pathologist :: Pennsylvania :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_2.html</link>
<description><![CDATA[Job 9598516-0001 CLIA certified lab seeks locums physician to cover full time staff.  Dates needed are about a few days up to a week for vacation coverage in the summer or fall.   Surgical Pathology, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_1.html">
<title>Excellent long term opportunity for Pathologist in Pennsylvania :: Pennsylvania :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_pennsylvania/page_1.html</link>
<description><![CDATA[Job 9597877-0001 Practice seeks locums Pathology physician to provide on-going coverage.  Responsibilities include Surgical Pathology, GU Pathology,GI Pathology, Dermatopathology, Cytology-GYN, Microbiology, ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_2.html">
<title>Facility in North Carolina seeks Dermatopathology coverage :: North Carolina :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_2.html</link>
<description><![CDATA[Job 9509606-0009 Private lab seeks locums Pathology physician to provide coverage beginning this summer and on-going.  Excellent opportunity for interested physician to explore permanent placement option. ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_2.html">
<title>Mississippi Facility in Need of Vacation Coverage - 2010 :: Mississippi :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_2.html</link>
<description><![CDATA[Job 0306977-0036 Comphealth will pay for and process your Mississippi license. Gyn-cytology is required.  Excellent support staff. Please call for additional details. We offer competitive pay that may ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_2.html">
<title>Excellent opportunity for Pathologist in South Carolina :: South Carolina :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_2.html</link>
<description><![CDATA[Job 9603966-0001 Group practice seeks locums Pathology physician to provide 3 - 4 months of coverage.  Surgical, Hematopathology, GU, and GI Pathology, and Dermatopathology.    CLIA certified lab 8am ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_1.html">
<title>Medical center in Mississippi seeks Pathology coverage :: Mississippi :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_mississippi/page_1.html</link>
<description><![CDATA[Job 9506700-0005 Locums Pathologist needed to cover full time physician's vacation.   Holiday coverage needed towards end of the year.   Surgical Path, Hempath, GU, GI and Dermpath  CLIA certified lab ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_mexico/page_1.html">
<title>Group practice seeks Pathology coverage in New Mexico :: New Mexico :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_mexico/page_1.html</link>
<description><![CDATA[Job 9609303-0001 Group seeks locums Pathologist for staff vacation coverage.  CLIA certified lab - Surgical, Hematopathology, GU and GI, Dermapathology and wide variety of others.  8am - 5pm Beautiful ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_york/page_1.html">
<title>Pathologist  needed for ongoing coverage in New York :: New York :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_new_york/page_1.html</link>
<description><![CDATA[Job 9500050-0098 Community based hospital laboratory needs locums coverage Jan through end of June.  Beautiful location in the Southern Tier of New York  January ongoing coverage need until permanent ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_1.html">
<title>Facility in North Carolina seeks Pathology coverage :: North Carolina :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_carolina/page_1.html</link>
<description><![CDATA[Job 9509606-0008 Private lab seeks locums GI Pathology physician to provide coverage beginning this summer and on-going.  Excellent opportunity for interested physician to explore permanent placement ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_florida/page_1.html">
<title>Facility in sunny Florida seeks Pathology coverage :: Florida :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_florida/page_1.html</link>
<description><![CDATA[Job 9509606-0011 Private lab seeks locums Pathology physician to provide coverage beginning this summer and on-going.  Excellent opportunity for Board Certified and Fellowship trained physician to explore ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_1.html">
<title>Maryland health system seeks Pathology coverage :: Maryland :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_1.html</link>
<description><![CDATA[Job 9607464-0001 Locums Pathologist needed to provide coverage beginning in August.  Need is on-going and there is an excellent potential for permanent placement.  Surgical, GU and GI Pathology.    8am ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_1.html">
<title>Locums Coverage Needed for 2010, Various Weeks :: South Carolina :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_south_carolina/page_1.html</link>
<description><![CDATA[Job 1666228-0002 Hospital based, non solo. Monday through Friday, possible call rotation. Bone marrow procedures are required. Must have experience with complex cases.  Excellent support staff. Please ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_louisiana/page_1.html">
<title>Government Pathology job in Shreveport, LA :: Louisiana :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_louisiana/page_1.html</link>
<description><![CDATA[Job 0911154-0153   Any active state license Board Certified Monday - Friday 7:00am - 3:30pm Call is 1:2 weeknights and weekends BLS is required All patient records are computerized so must type at least ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_georgia/page_1.html">
<title>Pathology coverage needed in Georgia :: Georgia :: Weatherby Locums</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_georgia/page_1.html</link>
<description><![CDATA[Job 9565622-0003 Lab has need for locums Dermatopathologist starting mid November through end of the year.  Candidate who is Board Certified is preferred.    Monday - Friday 8am - 5pm Call for more information! ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_3.html">
<title>GI Locums, Part  Time or Full Time :: Maryland :: CompHealth Inc</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_maryland/page_3.html</link>
<description><![CDATA[Job 1569784-0003 Working with several pathologists. No hospital. Must have extensive GI experience. Possibility of permanent opportunity.  Please call for additional details. We offer competitive pay ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_dakota/page_2.html">
<title>Call for Information :: North Dakota :: Inhouse Physician Recruiters Network</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_north_dakota/page_2.html</link>
<description><![CDATA[The In-House Physician Recruiter Network, composed of over 500 hospital recruiters, represents over 10,000 hospitals and clinics. Our Network's special feature is to showcase outstanding physicians (who ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_virginia/page_3.html">
<title>Statewide :: Virginia :: The Doctor Job</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_virginia/page_3.html</link>
<description><![CDATA[ Looking for a job in a big city?   Even if you've heard that a market is "saturated", we can help!  Many job openings  for physicians may be hidden and unavailable unless you know where to look. An excellent ]]></description>
</item>

<item rdf:about="http://www.physemp.com/physician_jobs/all_pathology_jobs_in_texas/page_2.html">
<title>Statewide :: Texas :: The Doctor Job</title>
<link>http://www.physemp.com/physician_jobs/all_pathology_jobs_in_texas/page_2.html</link>
<description><![CDATA[ Looking for a job in a big city?   Even if you've heard that a market is "saturated", we can help!  Many job openings  for physicians may be hidden and unavailable unless you know where to look. An excellent ]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/29">
<title>Activity of tannins from Stryphnodendron adstringens on Cryptococcus neoformans: effects on growth, capsule size and pigmentation</title>
<link>http://www.ann-clinmicrob.com/content/8/1/29</link>
<description><![CDATA[Background:
Stryphnodendron adstringens (Mart.) Coville, Leguminosae, also known in Brazil as barbatimao, is rich in tannins and many flavan-3-ols and proanthocyanidins such as prodelphinidins and prorobinetinidins. Previous studies have demonstrated several pharmacological properties of tannins from barbatimao, including anti-candidal activity.
Methods:
The antifungal activity of proanthocyanidin polymeric tannins from Stryphnodendron adstringens (subfraction F2.4) was evaluated against three strains of Cryptococcus neoformans with different capsule expressions, using the broth microdilution technique, light microscopy and transmission electron microscopy. The effect of subfraction F2.4 on C. neoformans and melanoma mammalian cells pigmentation was also evaluated.
Results:
Although susceptibility assays revealed MIC values quite similar (between 2.5 and 5.0 ug/ml), analyses of MFC values revealing that the acapsular mutant Cap 67 was more susceptible to be killed by the subfraction F2.4 (MFC = 20 ug/ml) than the two tested capsular strains (T1-444 and ATCC 28957) (MFC > 160 ug/ml). Optical and electron microscopy experiments revealed relevant alterations in cell shape and size in all strains treated with 1 and 2.5 ug/ml of subfraction F2.4. Capsule size of the capsular strains decreased drastically after subfraction F2.4 treatment. In addition, ultrastructural alterations such as cell wall disruption, cytoplasm extraction, mitochondria swelling, increase in the number of cytoplasmic vacuoles and formation of membranous structures in the cytoplasm were also observed in treated yeasts. Incubation with subfraction F2.4 also decreased C. neoformans pigmentation, however, did not interfere in melanization of B16F10 mammalian cells.
Conclusion:
Our data indicate that tannins extracted from S. adstringens interfered with growth, capsule size and pigmentation, all important virulence factors of C. neoformans, and may be considered as a putative candidate for the development of new antifungal agents.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/28">
<title>Application of a high throughput Alamar blue biofilm susceptibility assay to Staphylococcus aureus biofilms</title>
<link>http://www.ann-clinmicrob.com/content/8/1/28</link>
<description><![CDATA[Background:
Staphylococcus aureus and S. epidermidis biofilms differ in structure, growth and regulation, and thus the high-throughput method of evaluating biofilm susceptibility that has been published for S. epidermidis cannot be applied to S. aureus without first evaluating the assay's reproducibility and reliability with S. aureus biofilms.
Methods:
Staphylococcus aureus biofilms were treated with eleven approved antibiotics, lysostaphin, or Conflikt®, exposed to the oxidation reduction indicator Alamar blue, and reduction relative to untreated controls was determined visually and spectrophotometrically. The minimum biofilm inhibitory concentration (MBIC) was defined as ≤ 50% Alamar blue reduction and a purple/blue well 60 min after the addition of Alamar blue. Because all of the approved antibiotics had MBICs >128 μg/ml (most >2048 μg/ml), lysostaphin and Conflikt®, with relatively low MBICs, were used to correlate Alamar blue reduction with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduction and viable counts (CFU/ml) for S. aureus ATCC 29213 and three clinical isolates. Alamar blue's stability and lack of toxicity allowed CFU/ml to be determined from the same wells as Alamar blue absorbances.
Results:
Overall, Alamar blue reduction had excellent correlation with XTT reduction and with CFU/ml. For ATCC 29213 and two clinical isolates treated with lysostaphin or Conflikt®, Alamar blue reduction had excellent correlation with XTT reduction (r = 0.93-0.99) and with CFU/ml (r = 0.92-0.98). For one of the clinical isolates, the results were moderately correlated for Conflikt® (r = 0.76, Alamar blue vs. XTT; r = 0.81, Alamar blue vs. CFU/ml) and had excellent correlation for lysostaphin (r = 0.95, Alamar blue vs. XTT; r = 0.97, Alamar blue vs. CFU/ml).
Conclusion:
A reliable, reproducible method for evaluating biofilm susceptibility was successfully applied to S. aureus biofilms. The described method provides researchers with a simple, nontoxic, relatively inexpensive, high throughput measure of viability after drug treatment. A standardized biofilm Alamar blue assay should greatly increase the rate of discovery of S. aureus biofilm specific agents.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/27">
<title>Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: a prospective observational study

</title>
<link>http://www.ann-clinmicrob.com/content/8/1/27</link>
<description><![CDATA[Background:
The aims of this study were to determine the antimicrobial susceptibility patterns of urinary isolates from community acquired acute uncomplicated urinary tract infections (uUTI) and to evaluate which antibiotics were empirically prescribed in the outpatient management of uUTI.
Methods:
Among the patients which were admitted to outpatient clinics of Ankara University Medical Faculty, Ibni-Sina Hospital during 2005-2006, a total of 429 women between the age of 18 and 65 years old who were clinically diagnosed with uUTI and to whom prescribed empirical antibiotics were enrolled in this prospective observational study. Patients' demographical data, urine culture results, resistance rates to antimicrobial agents and prescribed empiric antimicrobial therapy were analyzed.
Results:
Totally 390 (90.9%) patients among all study population were requested for urine culture by their physicians. 150 (38.5%) of these urine cultures were positive. The most common isolated uropathogen was Escherichia coli (E. coli) (71.3%). The variations of uropathogens according to age and menopause status were not significantly different.The resistance rates of E. coli isolates for ampicillin, ampicillin-sulbactam, amoxicillin-clavulonate, cefuroxime, ceftriaxone, fluoroquinolones (FQ), co-trimoxazole (TMP-SMX) and gentamicin were 55.1%, 32.7%, 32.7%, 23.4%, 15.9%, 25.2%, 41.1%, 6.1% respectively. FQ were the most common prescribed antibiotics (77.9%) (P < 0.001), followed by TMP-SMX (10.7%), fosfomycin (9.2%), nitrofurantoin (2.1%). Treatment durations were statistically longer than the recommended 3-day course (P < 0.001).
Conclusion:
Empirical use of FQ in uUTI should be discouraged because of increased antimicrobial resistance rates.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/26">
<title>Prevalence and antimicrobial resistance pattern of bacterial meningitis in Egypt</title>
<link>http://www.ann-clinmicrob.com/content/8/1/26</link>
<description><![CDATA[Infectious diseases are the leading cause of morbidity and mortality in the developing world. In Egypt bacterial diseases constitute a great burden, with several particular bacteria sustaining the leading role of multiple serious infections. This article addresses profound bacterial agents causing a wide array of infections including but not limited to pneumonia and meningitis. The epidemiology of such infectious diseases and the prevalence of Streptococcus pneumoniae, Neisseria meningitidis and Haemophilus influenzae are reviewed in the context of bacterial meningitis. We address prevalent serotypes in Egypt, antimicrobial resistance patterns and efficacy of vaccines to emphasize the importance of periodic surveillance for appropriate preventive and treatment strategies.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/25">
<title>Correction: Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis</title>
<link>http://www.ann-clinmicrob.com/content/8/1/25</link>
<description><![CDATA[No description available]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/24">
<title>Fatal Chromobacterium violaceum septicaemia in northern Laos, a modified oxidase test and post-mortem forensic family G6PD analysis</title>
<link>http://www.ann-clinmicrob.com/content/8/1/24</link>
<description><![CDATA[Background:
Chromobacterium violaceum is a Gram negative facultative anaerobic bacillus, found in soil and stagnant water, that usually has a violet pigmented appearance on agar culture. It is rarely described as a human pathogen, mostly from tropical and subtropical areas.Case presentationA 53 year-old farmer died with Chromobacterium violaceum septicemia in Laos. A modified oxidase method was used to demonstrate that this violacious organism was oxidase positive. Forensic analysis of the glucose-6-phosphate dehydrogenase genotypes of his family suggest that the deceased patient did not have this possible predisposing condition.
Conclusion:
C. violaceum infection should be included in the differential diagnosis in patients presenting with community-acquired septicaemia in tropical and subtropical areas. The apparently neglected but simple modified oxidase test may be useful in the oxidase assessment of other violet-pigmented organisms or of those growing on violet coloured agar.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/23">
<title>Antifungal treatment for invasive Candida infections: a mixed treatment comparison meta-analysis</title>
<link>http://www.ann-clinmicrob.com/content/8/1/23</link>
<description><![CDATA[ObjectivesInvasive fungal infections are a major cause of mortality among patients at risk. Treatment guidelines vary on optimal treatment strategies. We aimed to determine the effects of different antifungal therapies on global response rates, mortality and safety.
Methods:
We searched independently and in duplicate 10 electronic databases from inception to May 2009. We selected any randomized trial assessing established antifungal therapies for confirmed cases of invasive candidiasis among predominantly adult populations. We performed a meta-analysis and then conducted a Bayesian mixed treatment comparison to differentiate treatment effectiveness. Sensitivity analyses included dosage forms of amphotericin B and fluconazole compared to other azoles.
Results:
Our analysis included 11 studies enrolling a total of 965 patients. For our primary analysis of global response rates, we pooled 7 trials comparing azoles to amphotericin B, Relative Risk [RR] 0.87 (95% Confidence Interval [CI], 0.78–0.96, P = 0.007, I2 = 43%, P = 0.09. We also pooled 2 trials of echinocandins versus amphotericin B and found a pooled RR of 1.10 (95% CI, 0.99–1.23, P = 0.08). One study compared anidulafungin to fluconazole and yielded a RR of 1.26 (95% CI, 1.06–1.51) in favor of anidulafungin. We pooled 7 trials assessing azoles versus amphotericin B for all-cause mortality, resulting in a pooled RR of 0.88 (95% CI, 0.74–1.05, P = 0.17, I2 = 0%, P = 0.96). Echinocandins versus amphotericin B (2 trials) for all-cause mortality resulted in a pooled RR of 1.01 (95% CI, 0.84–1.20, P = 0.93). Anidulafungin versus fluconazole resulted in a RR of 0.73 (95% CI, 0.48–1.10, P = 0.34). Our mixed treatment comparison analysis found similar within-class effects across all interventions. Adverse event profiles differed, with amphotericin B exhibiting larger adverse event effects.
Conclusion:
Treatment options appear to offer preferential effects on response rates and mortality. When mycologic data are available, therapy should be tailored.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/22">
<title>Hospital-associated methicillin-resistant Staphylococcus aureus  (HA-MRSA) in Italy </title>
<link>http://www.ann-clinmicrob.com/content/8/1/22</link>
<description><![CDATA[The aim of our study was to trace the dynamic changes of hospital-associated methicillin-resistant Staphylococcus aureus (HA-MRSA) lineages in Italy, comparing the genotypic backgrounds of contemporary isolates over a period of 17 years, with those of a sample of early MRSA strains from 1980.In total, 301 non-repetitive MRSA clinical isolates, recovered from 19 Italian hospitals between 1990 and 2007 were selected and analyzed for their antibiotic resistance, typed by PFGE and SCCmec, grouped into clonal-types and further characterized using Multi Locus Sequence Typing (MLST). A sample of fifteen early MRSA strains from 1980 was also used for comparison.The most interesting feature was the recent increase of ST228-MRSA-I (formerly the Italian clone; PFGE E) over the period 2000–2007 (57%), when compared to the period 1990–1999 (29%), and its stability to date, associated with a decrease of the highly epidemic ST247-MRSA-IA (formerly the Iberian clone; PFGE A), (23% from 1990 to 1999, 6% from 2000 to 2007). ST1-MRSA-I (1 out of 2 strains carrying ccrA2B2), ST8-MRSA-I (4 strains), ST15-MRSA-I (1 out of 4 carrying ccrA2B2) and ST30-MRSA-I (2 out of 5 carrying no ccrAB-types and ccrC) were the predominant earliest STs among the MRSA strains in 1980.A temporal shift in the susceptibility levels to glycopeptides was observed: strains with vancomycin MIC of ≥ 2 mg/L increased from 19.4% to 35.5%.In conclusion, we describe the alternation of MRSA clones that occurred in hospitals from 1990 to 2007 and the increase of the glycopeptide MIC levels, reflecting a worldwide trend. We document the detection of ST1, ST8, ST15 and ST30 in the 1980 isolates; we hypothesize their possible latency and their appearance as the current CA-MRSA clones.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/21">
<title>Genetic relatedness and molecular characterization of multidrug resistant Acinetobacter baumannii isolated in central Ohio, USA</title>
<link>http://www.ann-clinmicrob.com/content/8/1/21</link>
<description><![CDATA[Background:
Over the last decade, nosocomial infections due to Acinetobacter baumannii have been described with an increasing trend towards multidrug resistance, mostly in intensive care units. The aim of the present study was to determine the clonal relatedness of clinical isolates and to elucidate the genetic basis of imipenem resistance.
Methods:
A. baumannii isolates (n = 83) originated from two hospital settings in central Ohio were used in this study. Pulsed-field gel electrophoresis genotyping and antimicrobial susceptibility testing for clinically relevant antimicrobials were performed. Resistance determinants were characterized by using different phenotypic (accumulation assay for efflux) and genotypic (PCR, DNA sequencing, plasmid analysis and electroporation) approaches.
Results:
The isolates were predominantly multidrug resistant (>79.5%) and comprised of thirteen unique pulsotypes, with genotype VII circulating in both hospitals. The presence of blaOXA-23 in 13% (11/83) and ISAba1 linked blaOXA-66 in 79.5% (66/83) of clinical isolates was associated with high level imipenem resistance. In this set of OXA producing isolates, multidrug resistance was bestowed by blaADC-25, class 1 integron-borne aminoglycoside modifying enzymes, presence of sense mutations in gyrA/parC and involvement of active efflux (with evidence for the presence of adeB efflux gene).
Conclusion:
This study underscores the major role of carbapenem-hydrolyzing class D β-lactamases, and in particular the acquired OXA-23, in the dissemination of imipenem-resistant A. baumannii. The co-occurrence of additional resistance determinant could also be a significant threat.]]></description>
</item>

<item rdf:about="http://www.ann-clinmicrob.com/content/8/1/20">
<title>Isolation and identification of antimicrobial compound from Mentha longifolia L. leaves grown wild in Iraq</title>
<link>http://www.ann-clinmicrob.com/content/8/1/20</link>
<description><![CDATA[Background:
Mentha longifolia L. (Lamiaceae) leaves have been traditionally implemented in the treatment of minor sore throat and minor mouth or throat irritation by the indigenous people of Iraq, although the compounds responsible for the medicinal properties have not been identified. In the present study, an antimicrobial compound was isolated and characterized, and its biological activity was assessed.
Methods:
The compound was isolated and characterized from the extracted essential oil using different spectral techniques: TLC, FTIR spectra and HPLC. Antimicrobial activity of the compound was assessed using both disc diffusion and microdilution method in 96 multi-well microtiter plates.
Results:
A known compound was isolated from the essential oil of the plant and was identified as (-) menthol. The isolated compound was investigated for its antimicrobial activity against seven selected pathogenic and non-pathogenic microorganisms: Staphylococcus aureus, Streptococcus mutans, Streptococcus faecalis, Streptococcus pyogenis, Lactobacillus acidophilus, Pseudomonas aeruginosa and the yeast Candida albicans. Menthol at different concentrations (1:1, 1:5, 1:10, 1:20) was active against all tested bacteria except for P. aeruginosa, and the highest inhibitory effect was observed against S. mutans (zone of inhibition: 25.3 mm) using the disc diffusion method. Minimal inhibitory concentration MIC values ranged from 15.6–125.0 μg/ml, and the most promising results were observed against S. aureus and S. mutans (MIC 15.6 μg/ml) while, S. faecalis, S. pyogenis and L. acidophilus ranked next (MIC 31.2 μg/ml). Furthermore, menthol achieved considerable antifungal activity against the yeast C. albicans (zone of inhibition range: 7.1–18.5 mm; MIC: 125.0).
Conclusion:
The isolation of an antimicrobial compound from M. longifolia leaves validates the use of this plant in the treatment of minor sore throat and minor mouth or throat irritation.]]></description>
</item>

</rdf:RDF>